(Total Views: 1060)
Posted On: 11/30/2020 9:46:49 AM
Post# of 154164
Re: EmergingGrowth #66659
From the linked article:
"Although the data is still unblinded the drug has been through two Drug Safety Monitoring Committee (DSMC) meetings that indicate the drug is meeting its endpoint and thereby likely to be approved. In the interim, no patients can get the drug via emergency IND because the FDA has stopped that access. This is a point of moral outrage. By not looking at the interim data for leronlimab in an urgent fashion the FDA is condemning thousands of people to death daily. Although many drugs have gotten EUA’s only remdesivir has gotten FDA approval. Leronlimab is superior to remdesivir in safety and efficacy in moderate to critical patients and could be the next drug approved. The only question is when."
"The first drug that takes dying from COVID-19 off the table should be worth north of $10 billion ($17.00/share). "
"Although the data is still unblinded the drug has been through two Drug Safety Monitoring Committee (DSMC) meetings that indicate the drug is meeting its endpoint and thereby likely to be approved. In the interim, no patients can get the drug via emergency IND because the FDA has stopped that access. This is a point of moral outrage. By not looking at the interim data for leronlimab in an urgent fashion the FDA is condemning thousands of people to death daily. Although many drugs have gotten EUA’s only remdesivir has gotten FDA approval. Leronlimab is superior to remdesivir in safety and efficacy in moderate to critical patients and could be the next drug approved. The only question is when."
"The first drug that takes dying from COVID-19 off the table should be worth north of $10 billion ($17.00/share). "
(9)
(0)
